ID   INT-MEL-20
AC   CVCL_C668
SY   Me1007; ME1007; ME-1007; ME 1007; Mel-007; Mel007
DR   BTO; BTO_0005711
DR   EFO; EFO_0022590
DR   Cosmic; 889005
DR   Wikidata; Q54897767
RX   DOI=10.13130/grazia-giulia_phd2016-02-18;
RX   DOI=10.1007/0-306-46872-7_16;
RX   PubMed=2469723;
RX   PubMed=7520026;
RX   PubMed=8980186;
RX   PubMed=9725211;
RX   PubMed=15048078;
RX   PubMed=22383533;
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; None_reported; -; Zygosity=- (PubMed=15048078; PubMed=22383533).
CC   Sequence variation: Mutation; HGNC; HGNC:7989; NRAS; None_reported; -; Zygosity=- (PubMed=15048078; PubMed=22383533).
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   70Y
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 19-12-24; Version: 17
//
RX   DOI=10.13130/grazia-giulia_phd2016-02-18;
RA   Grazia G.;
RT   "Co-targeting of oncogenic and death receptors pathways in human
RT   melanoma: pre-clinical rationale for a pro-apoptotic and anti-angiogenic
RT   strategy.";
RL   Thesis PhD (2015); Universita degli studi di Milano; Milano; Italy.
//
RX   DOI=10.1007/0-306-46872-7_16;
RA   Anichini A., Mortarini R., Vegetti C., Molla A., Borri A., Parmiani G.;
RT   "Melanoma: the Milan melanoma cell lines.";
RL   (In book chapter) Human cell culture. Vol. 1. Cancer cell lines part 1; Masters J.R.W., Palsson B.O. (eds.); pp.283-292; Kluwer Academic Publishers; New York; USA (1999).
//
RX   PubMed=2469723; DOI=10.4049/jimmunol.142.10.3692;
RA   Anichini A., Mazzocchi A., Fossati G., Parmiani G.;
RT   "Cytotoxic T lymphocyte clones from peripheral blood and from tumor
RT   site detect intratumor heterogeneity of melanoma cells. Analysis of
RT   specificity and mechanisms of interaction.";
RL   J. Immunol. 142:3692-3701(1989).
//
RX   PubMed=7520026; DOI=10.1002/ijc.2910580413;
RA   Hersey P., Si Z.-Y., Smith M.J., Thomas W.D.;
RT   "Expression of the co-stimulatory molecule B7 on melanoma cells.";
RL   Int. J. Cancer 58:527-532(1994).
//
RX   PubMed=8980186; DOI=10.1002/(SICI)1097-0215(19961211)68:6<795::AID-IJC18>3.0.CO;2-#;
RA   Thomas W.D., Smith M.J., Si Z.-Y., Hersey P.;
RT   "Expression of the co-stimulatory molecule CD40 on melanoma cells.";
RL   Int. J. Cancer 68:795-801(1996).
//
RX   PubMed=9725211; DOI=10.4049/jimmunol.161.5.2195;
RA   Thomas W.D., Hersey P.;
RT   "TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in
RT   Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of
RT   target cells.";
RL   J. Immunol. 161:2195-2200(1998).
//
RX   PubMed=15048078; DOI=10.1038/sj.onc.1207563;
RA   Pavey S., Johansson P., Packer L., Taylor J., Stark M.S., Pollock P.M.,
RA   Walker G.J., Boyle G.M., Harper U., Cozzi S.-J., Hansen K., Yudt L.,
RA   Schmidt C., Hersey P., Ellem K.A.O., O'Rourke M.G.E., Parsons P.G.,
RA   Meltzer P.S., Ringner M., Hayward N.K.;
RT   "Microarray expression profiling in melanoma reveals a BRAF mutation
RT   signature.";
RL   Oncogene 23:4060-4067(2004).
//
RX   PubMed=22383533; DOI=10.1158/1535-7163.MCT-11-0676;
RA   Dutton-Regester K., Irwin D., Hunt P., Aoude L.G., Tembe V.,
RA   Pupo G.M., Lanagan C., Carter C.D., O'Connor L., O'Rourke M.,
RA   Scolyer R.A., Mann G.J., Schmidt C.W., Herington A., Hayward N.K.;
RT   "A high-throughput panel for identifying clinically relevant mutation
RT   profiles in melanoma.";
RL   Mol. Cancer Ther. 11:888-897(2012).
//